The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology

Trends in Immunology

Volumn 30, Issue 8, 2009, Pages 383-391

  Vereecke, Lars ^a,b   Beyaert, Rudi ^a,b   van Loo, Geert ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UBIQUITIN EDITING ENZYME A20; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CROHN DISEASE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NF-KAPPA B; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68149139538     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2009.05.007     Document Type: Review

References (83)

1. Hayden M.S., and Ghosh S. Shared principles in NF-κB signaling. Cell 132 (2008) 344-362
2. Verstrepen L., et al. TLR-4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme. Cell. Mol. Life Sci. 65 (2008) 2964-2978
3. Pasparakis M., et al. Dissection of the NF-κB signalling cascade in transgenic and knockout mice. Cell Death Differ. 13 (2006) 861-872
4. Renner F., and Schmitz M.L. Autoregulatory feedback loops terminating the NF-κB response. Trends Biochem. Sci. 34 (2009) 128-135
5. Coornaert B., et al. A20: central gatekeeper in inflammation and immunity. J. Biol. Chem. 284 (2009) 8217-8221
6. Lee E.G., et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289 (2000) 2350-2354
7. Hitotsumatsu O., et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28 (2008) 381-390
8. Turer E.E., et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J. Exp. Med. 205 (2008) 451-464
9. Saitoh T., et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J. Immunol. 174 (2005) 1507-1512
10. Lin R., et al. Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J. Biol. Chem. 281 (2006) 2095-2103
11. Onose A., et al. An inhibitory effect of A20 on NF-κB activation in airway epithelium upon influenza virus infection. Eur. J. Pharmacol. 541 (2006) 198-204
12. Breckpot K., et al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol. 182 (2009) 860-870
13. Song X.T., et al. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 14 (2008) 258-265
14. Wertz I.E., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430 (2004) 694-699
15. Bertrand M.J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30 (2008) 689-700
16. Newton K., et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134 (2008) 668-678
17. Li L., et al. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta 1793 (2009) 346-353
18. Boone D.L., et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5 (2004) 1052-1060
19. Zetoune F.S., et al. A20 inhibits NF-κB activation downstream of multiple Map3 kinases and interacts with the IκB signalosome. Cytokine 15 (2001) 282-298
20. Wullaert A., et al. Ubiquitin: tool and target for intracellular NF-κB inhibitors. Trends Immunol. 27 (2006) 533-540
21. Jin Z., et al. Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling. Cell 137 (2009) 721-735
22. Wagner S., et al. Ubiquitin binding mediates the NF-κB inhibitory potential of ABIN proteins. Oncogene 27 (2008) 3739-3745
23. Iha H., et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-κB activation. EMBO J. 27 (2008) 629-641
24. Shembade N., et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 9 (2008) 254-262
25. Shembade N., et al. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-κB signalling. EMBO J. 28 (2009) 513-522
26. Coornaert B., et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nat. Immunol. 9 (2008) 263-271
27. Strober W., et al. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20 (2002) 495-549
28. Rakoff-Nahoum S., and Medzhitov R. Role of the innate immune system and host-commensal mutualism. Curr. Top. Microbiol. Immunol. 308 (2006) 1-18
29. Rakoff-Nahoum S., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
30. Nenci A., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446 (2007) 557-561
31. Zaph C., et al. Epithelial-cell-intrinsic IKKβ expression regulates intestinal immune homeostasis. Nature 446 (2007) 552-556
32. Steinbrecher K.A., et al. Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J. Immunol. 180 (2008) 2588-2599
33. The Welcome Trust Case Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678
34. Barmada M.M., et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm. Bowel Dis. 10 (2004) 513-520
35. Arsenescu R., et al. Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol. 1 (2008) 399-411
36. Trynka G., et al. Coeliac disease associated risk variants in TNFAIP3 and REL implicate altered NF-κB signalling. Gut 58 (2009) 1078-1083
37. Elliott M.J., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
38. Elliott M.J., et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344 (1994) 1125-1127
39. Plenge R.M., et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat. Genet. 39 (2007) 1477-1482
40. Thomson W., et al. Rheumatoid arthritis association at 6q23. Nat. Genet. 39 (2007) 1431-1433
41. Orozco G., et al. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum. Mol. Genet. 18 (2009) 2693-2699
42. Dieguez-Gonzalez R., et al. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res. Ther. 11 (2009) R42
43. Graham R.R., et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 40 (2008) 1059-1061
44. Musone S.L., et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 40 (2008) 1062-1064
45. Bates, J.S. et al. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. (in press) doi: 10.1038/gene.2009.31
46. Hom G., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358 (2008) 900-909
47. Mathis D., et al. β-Cell death during progression to diabetes. Nature 414 (2001) 792-798
48. Eldor R., et al. Conditional and specific NF-κB blockade protects pancreatic β cells from diabetogenic agents. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5072-5077
49. Fung E.Y.M.G., et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 10 (2009) 188-191
50. Grey S.T., et al. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J. Exp. Med. 190 (1999) 1135-1146
51. Grey S.T., et al. Genetic engineering of a suboptimal islet graft with A20 preserves β cell mass and function. J. Immunol. 170 (2003) 6250-6256
52. Yu L.Y., et al. Direct transfer of A20 gene into pancreas protected mice from streptozotocin-induced diabetes. Acta Pharmacol. Sin. 25 (2004) 721-726
53. Liuwantara D., et al. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection. Diabetes 55 (2006) 2491-2501
54. Lowes M.A., et al. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
55. Nair R.P., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 41 (2009) 199-204
56. Wang H., et al. A 9-centimorgan interval of chromosome 10 controls the T cell-dependent psoriasiform skin disease and arthritis in a murine psoriasis model. J. Immunol. 180 (2008) 5520-5529
57. Idel S., et al. A20, a regulator of NF-κB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14235-14240
58. Gelfand J.M., et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 296 (2006) 1735-1741
59. Abou-Raya A., and Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun. Rev. 5 (2006) 331-337
60. Stamler J., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
61. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6 (2006) 508-519
62. de Winther M.P., et al. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 904-914
63. Dansky H.M., et al. A phenotype-sensitizing ApoE-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse. Genetics 160 (2002) 1599-1608
64. Teupser D., et al. Atherosclerosis quantitative trait loci are sex- and lineage-dependent in an intercross of C57BL/6 and FVB/N low-density lipoprotein receptor-/- mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 123-128
65. Wolfrum S., et al. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-κB target genes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 18601-18606
66. Michelsen K.S., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10679-10684
67. Bjorkbacka H., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 10 (2004) 416-421
68. Mullick A.E., et al. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 115 (2005) 3149-3156
69. Boonyasrisawat W., et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 56 (2007) 499-505
70. Ozaki K., et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat. Genet. 32 (2002) 650-654
71. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006) 431-436
72. Honma K., et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24. 1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer 47 (2008) 1-7
73. Chanudet E., et al. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J. Pathol. 217 (2009) 420-430
74. Novak U., et al. The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. Blood (2009) 10.1182/blood-2008-08-174110
75. Kato M., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459 (2009) 712-716
76. Schmitz R., et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 206 (2009) 981-989
77. Thelander E.F., et al. Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia. Leuk. Lymphoma 49 (2008) 477-487
78. Compagno M., et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459 (2009) 717-721
79. Rahighi S., et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 136 (2009) 1098-1109
80. Tokunaga F., et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat. Cell Biol. 11 (2009) 123-132
81. Sun S.C. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8 (2008) 501-511
82. Keating S.E., et al. IRAK-2 participates in multiple toll-like receptor signaling pathways to NF-κB via activation of TRAF6 ubiquitination. J. Biol. Chem. 282 (2007) 33435-33443
83. Chen Z.J., and Sun L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33 (2009) 275-286